Becton, Dickinson and Company (NYSE:BDX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings data on Monday. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10, FiscalAI reports. The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.43 earnings per share. Becton, Dickinson and Company updated its FY 2026 guidance to 12.350-12.650 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• Closed the life sciences combination with Waters, receiving a $4.0 billion cash distribution and announcing deployment of $2.0 billion to share repurchases (ASR) and $2.0 billion to debt paydown, supporting capital returns and balance-sheet strengthening.
• Q1 revenue was $5.3 billion (up 0.4%) with New BD +2.5% and adjusted EPS $2.91 beating expectations; fiscal 2026 guidance for New BD calls for low single-digit revenue growth, ~25% adjusted operating margin, and adjusted EPS of $12.35–$12.65 (midpoint ≈ +6%).
• Commercial and innovation momentum across high-growth platforms — double-digit growth in biologic drug delivery, PureWick, advanced tissue regeneration, and pharmacy automation; Pyxis Pro launch showing strong competitive conversions and BD has >80 GLP‑1 molecules contracted in delivery devices.
• Operational improvements driving margin and cash-flow — BD Excellence delivered ~8% productivity improvement this quarter, manufacturing network reduced to under 50 global sites, and $150M (75%) of a $200M cost-out program already executed.
• Headwinds remain in about 10% of the portfolio — Alaris remediation, lower vaccine demand and China VBP dynamics, plus tariffs (roughly 170 bps hit to gross margin and a material EPS drag) which management says temper near-term results.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $171.55 on Wednesday. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $235.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.64 and a current ratio of 1.05. The company has a market capitalization of $48.88 billion, a P/E ratio of 27.99, a P/E/G ratio of 2.72 and a beta of 0.25. The business’s 50-day moving average is $199.76 and its two-hundred day moving average is $192.43.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s payout ratio is currently 68.52%.

Becton, Dickinson and Company announced that its board has approved a stock repurchase plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q1 / recent-quarter beat — BD reported EPS and sales slightly above consensus and noted improving margins, which supports the core business outlook. What’s Going On With Becton Dickinson Stock Tuesday?
• Positive Sentiment: High‑profile endorsement — TV commentator Jim Cramer expressed a favorable view on the “new company” after the transaction, which can lift investor sentiment among retail flows. Jim Cramer on Becton, Dickinson
• Positive Sentiment: New coverage — Barclays initiated coverage with an Overweight / $202 PT, providing incremental institutional support. Barclays Overweight on BDX
• Neutral Sentiment: Spin‑off / combination completed — BD completed the separation and combination of its Biosciences & Diagnostic Solutions business with Waters, a strategic move that reshapes BD’s business mix and cash profile. Investors will be re‑rating the company post‑transaction. BD Completes Combination with Waters
• Neutral Sentiment: Debt tender offers — BD launched cash tender offers to buy up to $1.6 billion of outstanding debt, a balance‑sheet move that may reduce interest burden/maturity risk but uses corporate cash. BD Announces Tender Offers
• Negative Sentiment: FY‑2026 guidance cut — Management set FY‑2026 EPS guidance at $12.35–$12.65, below street expectations and reflecting the divestiture, which materially reduced consensus numbers and is the main driver of weaker forward sentiment. Reuters: Becton Dickinson cuts annual profit forecast
• Negative Sentiment: Analyst pressure — multiple firms trimmed price targets and adjusted ratings (JPMorgan, Wells Fargo, Jefferies adjustments noted), increasing near‑term sell pressure and volatility. Benzinga: What’s Going On With Becton Dickinson Stock?

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 2,463 shares of company stock worth $501,530. 0.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of large investors have recently bought and sold shares of BDX. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Brooklyn Investment Group grew its stake in Becton, Dickinson and Company by 73.4% in the 3rd quarter. Brooklyn Investment Group now owns 2,613 shares of the medical instruments supplier’s stock valued at $489,000 after acquiring an additional 1,106 shares during the period. Shay Capital LLC acquired a new stake in Becton, Dickinson and Company in the 2nd quarter valued at $431,000. CTC Alternative Strategies Ltd. purchased a new stake in Becton, Dickinson and Company in the 2nd quarter worth $382,000. Finally, State of Wyoming acquired a new position in Becton, Dickinson and Company during the second quarter worth $352,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on BDX. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Citigroup reduced their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday. Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Wells Fargo & Company reduced their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Finally, JPMorgan Chase & Co. lowered their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $196.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.